Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
The case alleges Navan failed to disclose it would increase its sales and marketing expenses by 39% just months after the IPO.
-
The CoreWeave class action alleges that defendants overstated CoreWeave’s ability to meet customer demand for its service.
-
The case alleges Enphase Energy misled investors about channel inventory and its ability to mitigate the 25D tax credit’s termination.
-
The case alleges that defendants created the false impression that they possessed reliable information regarding PayPal’s projected revenue and growth.
-
The case alleges that NuScale failed to disclose that it entrusted its NPM commercialization to an entity that lacked significant prior experience.
-
The Varonis lawsuit alleges that defendants created the false impression that they possessed reliable information regarding projected revenue, growth.
-
Ultragenyx allegedly misled investors about setrusumab’s potential Phase 3 study success in reducing fracture rates.
-
The Soleno complaint alleges that Soleno Phase 3 clinical trial program for DCCR had downplayed, misrepresented, and/or concealed safety concerns.
-
The Eos Energy complaint alleges that Eos Energy was unable to achieve the ramp in production and capacity utilization required to achieve guidance.
-
The case alleges Ardent Health misled investors by overstating accounts receivable and concealing insufficient medical malpractice insurance.